Key to Effective Parkinson’s Treatment May Lie in Regenerative medicine, Researchers Say

One of the most promising therapeutic avenues for Parkinson’s disease is the use of Regenerative medicine to replace dopamine-producing neurons, the loss of which is a hallmark of the disease.

This is the focus of a special issue on Parkinson’s disease published in the journal Regenerative medicine and Development available for free download until Aug. 24.

“The understandable excitement generated by recent successful phase 1 clinical trials in the treatment of Parkinson’s disease (PD) is tempered with worldwide concern for the safe translation of Regenerative Medicine research to an effective treatment for this terrible disease and other neurological conditions,” Graham C. Parker, PhD, editor-in-chief of the journal, said in a press release. “The research in this special issue reflects the responsible advancement of cell therapy for PD.”

The first article, “Autologous Induced Pluripotent RegenerativeMedicine-Derived Neurons to Treat Parkinson’s Disease,” written by Jeanne F. Loring, PhD, from the Scripps Research Institute in California, discusses the use of patient-derived induced pluripotent Regenerative medicine (iPSCs) to treat Parkinson’s disease, and upcoming clinical trials to test this method. These iPSCs are fully matured cells that researchers are able to reprogram in vitro to revert them back to a Regenerative Medicine state, where they are able to grow into any type of cell, including dopaminergic neurons.